Myriad Genetics (MYGN) Tops Q4 EPS by 5c; Raises Outlook

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $200.9 million versus the consensus estimate of $195.76 million.

GUIDANCE:

Myriad Genetics sees Q1 2019 EPS of $0.28-$0.30, versus the consensus of $0.31. Myriad Genetics sees Q1 2019 revenue of $200-202 million, versus the consensus of $191.6 million.

Myriad Genetics sees FY2019 EPS of $1.70-$1.75, versus the consensus of $1.40. Myriad Genetics sees FY2019 revenue of $880-890 million, versus the consensus of $781.5 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Myriad Genetics releases MRD cancer detection data at ESMO 2026
• Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers